Scholar Rock Holding buy Cantor Fitzgerald
Start price
17.07.25
/
50%
€35.00
Target price
17.07.26
-
Performance (%)
-20.57%
Price
14.08.25
€27.80
Summary
This prediction is currently active. The prediction for Scholar Rock Holding disappoints with a performance of -20.57%. This prediction currently runs until 17.07.26. The prediction end date can be changed by Cantor_Fitzgerald at any time. Cantor_Fitzgerald has 50% into this predictionScholar Rock is a clinical-stage biopharmaceutical company that engages in the discovery and development of innovative medicines to treat serious diseases in patients that currently have limited or no treatment options. Their pipeline consists of a number of product candidates that target growth factor signaling pathways within the human body. These products hold potential for the treatment of multiple diseases, including neuromuscular disorders, cancer, and fibrosis. Scholar Rock, which trades under the symbol SRRK, is listed on the NASDAQ stock exchange.
Performance without dividends (%)
| Name | 1w |
|---|---|
| Scholar Rock Holding | 2.963% |
| iShares Core DAX® | 0.998% |
| iShares Nasdaq 100 | 1.965% |
| iShares Nikkei 225® | 4.258% |
| iShares S&P 500 | 2.037% |
Comments by Cantor_Fitzgerald for this prediction
In the thread Scholar Rock Holding diskutieren
Scholar Rock Holding Corporation (NASDAQ: SRRK) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating on the stock.
Ratings data for SRRK provided by MarketBeat